Agency Investigates Diabetes Treatment Drug Lantus
The European Medicines Agency (EMEA) today released a statement updating its position on Sanofi-Aventis' diabetes treatment drug Lantus. EMEA looked at four studies related to Lantus. Two of these studies found an association with breast cancer. Chris Viehbacher, the CEO of Sanofi-Aventis, today mounted to defend Lantus in the face of investors and the financial community.
In a story published at Lepoint.fr Chris Viehbacher says that the EMEA has not asked the patients in the Lantus study to change treatment. The topic is very important both for the financial community, patients and Sanofi-Aventis as because of the popularity of Lantus. The drug in 2008 has reached a turnover of 2.45 billion euros.
He also spoke of "poor quality" of studies published Friday and reiterated that Sanofi-Aventis will continue to monitor the safety of Lantus in collaboration with diabetologists and oncologists.
This is what EMEA has published today that had promoted a sharp defense from Sanofi-Aventis.
The European Medicines Agency (EMEA) is looking into four recently published registry studies investigating a possible relationship between insulin analogues, in particular insulin glargine, and the risk of cancer. The studies were published on the Diabetologia website on 26 June 2009.
Insulin glargine is a long-acting insulin analogue, authorised in the European Union (EU) as Lantus and Optisulin, for the treatment of adults, adolescents and children aged six years or above with diabetes, when treatment with insulin is required.
The results of the four studies were found to be inconsistent. In two studies (Scottish Diabetes Research Network Epidemiology Group and Jonasson et al) an association between breast cancer was found in a group of patients taking insulin glargine as monotherapy, but not in another group of patients using insulin glargine together with other types of insulin. For other cancers, no association was found. In these two studies dose-dependency was not evaluated. The third study (Hemkens et al) reported a dose-dependent association between use of insulin glargine and malignancies. However, no information is available on the types of cancer found in this study. In the fourth study (Currie et al), no association between cancer (either breast, colorectal, pancreatic or prostate cancer) and the use of insulin glargine, or any other insulin, was found.
On the basis of the currently available data, a relationship between insulin glargine and cancer cannot be confirmed nor excluded. However, the concerns raised by the four studies require further in-depth evaluation.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) will perform a detailed assessment of the studies’ results and any other relevant information. This review will also address issues, such as dose-response effects, the implications of the relatively short duration of the studies and influence of other factors on the risk of breast cancer and other cancers (e.g. age, body mass index (BMI), menopausal status, parity, socioeconomic status).
The Marketing Authorisation Holder for Lantus and Optisulin, Sanofi-Aventis, has been asked to comment on this potential safety concern.
Patients being treated with insulin glargine are advised to continue their treatment as normal. At this time there is no recommendation that patients should change their current treatment. In case of any concerns, patients should consult their doctor.
Further information will be provided once the CHMP has concluded its review. The articles are available online here: http://www.diabetologia-journal.org/cancer.html
Written by Armen Hareyan
Materials from LePoint.fr and EMEA are used in this report